LVZPF

$5.22+$1.79 (+52.19%)prev close

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

52-week range

$5.22 – $5.22

Exchange

OTC Link

Change+$2.67

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$12.7B	+4.1%	$2.50	$2.28–$2.60	2.1×	1
2027	$13.3B	+4.9%	$2.68	$2.44–$2.79	1.9×	1
2028	$14.2B	+6.8%	$2.95	$2.69–$3.07	1.8×	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Beat consensus in 3 of the last 7 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-04-23	$0.10	$0.09	-9.7%
2026-03-24	$0.05	$0.04	-18.9%
2025-10-23	$0.08	$0.07	-13.3%
2025-08-20	$0.08	$0.10	+21.1%
2025-04-23	$0.10	$0.10	+1.4%
2024-10-23	$0.08	$0.08	-5.3%
2024-08-22	$0.08	$0.08	+3.6%

Intrinsic value

$11.31

Price

$5.22

Implied upside

+117%

Symbol	Price	Today	Mkt cap	P/E
LVZPFLivzon Pharmaceutical Group Inc.	$5.22	+0.00%	$6.1B	—
NBIXNeurocrine Biosciences, Inc.	$152.72	+1.26%	$15.4B	—
SFOSFShanghai Fosun Pharmaceutical (Group) Co., Ltd.	$1.95	+0.00%	$5.2B	—
SHTDFSinopharm Group Co. Ltd.	$2.13	+0.00%	$6.6B	—
SHWGFShandong Weigao Group Medical Polymer Company Limited

No one on the platform currently holds LVZPF.

Institutions holding (13F)

No tracked institution reports a position in LVZPF as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

TTM yield · 82.83% ($4.32/share)

Execution date	Ratio
2018-06-25	13-for-10

No one on the platform has traded LVZPF yet.